Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674451 · ClinicalTrials.gov registry record · NA
Remote Ischemic Preconditioning to Prevent Contrast Nephropathy
A NA study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT02674451: Clinical Trial NA study, sponsored by Johns Hopkins University.
NCT02674451 is a NA study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02674451, a NA study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
Contrast-medium induced nephropathy (CIN) is a frequent and devastating complication of coronary angiography, occurring in 10-50% of cases. As would be expected, the incidence of CIN is much higher in patients with underlying renal dysfunction. Multiple trials have found CIN to be an independent predictor of prolonged hospitalization and both 30 day and 1 year mortality in patients with coronary artery disease. Intravenous contrast dye is felt to cause renal ischemia as the mechanism of injury. Unfortunately, despite the significant morbidity and mortality with CIN, there are few therapeutic interventions to reduce the risk with the exception of hydration and high dose statin therapy. Recently, remote ischemic preconditioning (RIPC), a process of inducing transient arm ischemia by inflating a blood pressure cuff to 200 mmHg for 3 repetitive 5 minute cycles, leads to a systemic cytoprotective response and ultimately reduces ischemic renal injury, myocardial injury, and even cerebral injury following coronary bypass grafting. While there is significant data supporting the role of RIPC in reducing systemic ischemic injury in surgical patients, there is only one small trial studying RIPC in patient's undergoing coronary angiography. The investigators hypothesize that RIPC will reduce the incidence of contrast-induced nephropathy in patients with baseline renal dysfunction undergoing coronary angiography for stable or unstable coronary artery disease.
Interventions
- PROCEDURE Remote ischemic preconditioning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-08-12 |
| Est. Completion | 2017-05-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02674451
The ClinicalTrials.gov registry entry for NCT02674451 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remote ischemic preconditioning is the first listed.
NCT02674451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02674451 about?
NCT02674451 is a clinical study titled "Remote Ischemic Preconditioning to Prevent Contrast Nephropathy". Contrast-medium induced nephropathy (CIN) is a frequent and devastating complication of coronary angiography, occurring in 10-50% of cases. As would be expected, the incidence of CIN is much higher in patients with underlying renal dysfunction. Multiple trials have found CIN to be an independent pre...
What is the current status of trial NCT02674451?
This trial is currently terminated. It is a NA study. The enrollment target is 44 participants. The study started on 2014-08-12. Estimated completion is 2017-05-11.
What interventions are being tested in trial NCT02674451?
The interventions under investigation include: Remote ischemic preconditioning (PROCEDURE).
Who is sponsoring clinical trial NCT02674451?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.